Gold Kelly purchased $11K of CAMP
Gold Kelly (Chief Financial Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market purchase details (shares, price, total value) and post-transaction holdings; there is no operational or financial update included.
Market read
Traders may treat the insider buy as a small positive signal, but without additional company catalysts it is unlikely to drive a sustained repricing.
What to watch
The filing does not disclose intent, timing constraints, or whether the purchase is part of a broader pattern; traders should compare with prior insider activity and overall liquidity/float.
Background
The article is a SEC Form 4 insider transaction disclosure for Camp4 Therapeutics (CAMP).
Ticker impact
Camp4 Therapeutics CFO Gold Kelly filed a Form 4 for an open-market purchase of 6,551 shares at $1.65 on 2026-08-03.
Near-term impact likely limited; any effect would be incremental sentiment rather than a re-rating catalyst.
Form 4 shows a direct open-market purchase with disclosed price and size, but no accompanying guidance, deal, or operational change is provided.
Market effects
No sector-wide implications; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Insider open-market buys can be routine liquidity or diversification, and the absence of a 10b5-1 plan does not guarantee a strong forward view.
Key entities
- issuerCamp4 Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderGold Kelly
Chief Financial Officer who reported the purchase.